Question 1

Does TD Asset Management own MLTX stock?

Accepted Answer

Yes. As of its Q2 2026 13F, TD Asset Management holds 128,274 shares of MLTX (MoonLake Immunotherapeutics), worth $2.5M.

Question 2

How many shares of MLTX does TD Asset Management own?

Accepted Answer

As of its Q2 2026 13F, TD Asset Management holds 128,274 shares of MLTX (MoonLake Immunotherapeutics).

Question 3

What is TD Asset Management's MLTX position worth?

Accepted Answer

As of its Q2 2026 13F, TD Asset Management's MLTX position is worth $2.5M.

Question 4

Is TD Asset Management buying or selling MLTX?

Accepted Answer

In Q2 2026, TD Asset Management reduced its MLTX position by 14,432 shares (-10.1%).

Question 5

When did TD Asset Management first buy MLTX?

Accepted Answer

TD Asset Management first reported MLTX in its Q2 2022 13F and has listed it in 17 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	128,274	-10.1%	$2.5M	0.0%	$19.47	0
2026-Q1	Increased	142,706	+12.6%	$2.7M	0.0%	$18.64	30
2025-Q4	Increased	126,744	+18.9%	$1.7M	0.0%	$13.18	30
2025-Q3	Decreased	106,610	-42.7%	$764,394	0.0%	$7.17	0
2025-Q2	Decreased	186,152	-14.2%	$8.8M	0.0%	$47.20	0
2025-Q1	Decreased	216,904	-17.1%	$8.5M	0.0%	$39.07	0
2024-Q4	Increased	261,634	+21.2%	$14.2M	0.0%	$54.15	34
2024-Q3	Increased	215,834	+3.1%	$10.7M	0.0%	$49.40	29